On February 11, 2026, the clinical laboratory landscape is recalibrating following a whirlwind 48 hours of financial and regulatory news. Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, finds itself at the epicenter of this shift. Following a blowout fourth-quarter earnings report yesterday and a last-minute legislative reprieve regarding Medicare reimbursement [...]
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.
Shares of healthcare diagnostics company Quest Diagnostics (NYSE:DGX)
jumped 6.8% in the afternoon session after the company reported strong fourth-quarter financial results and offered an upbeat forecast for 2026. For the fourth quarter, Quest's revenue grew 7.1% year-on-year to $2.81 billion, surpassing analyst estimates. Its adjusted earnings of $2.42 per share also came in ahead of expectations. Looking forward, the company's full-year 2026 revenue guidance was a notable highlight, coming in 3.3% above consensus estimates. The earnings guidance for the upcoming year also topped forecasts, signaling management's confidence in sustained performance.
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) announced better-than-expected revenue in Q4 CY2025, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations.
However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Quest trades at $179.96 and has moved in lockstep with the market. Its shares have returned 6.9% over the last six months while the S&P 500 has gained 11.3%.
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q3, starting with Quest (NYSE:DGX).
Quest Diagnostics (DGX) offers a reliable dividend with a strong yield, backed by consistent growth, solid profitability, and a sustainable payout ratio for income investors.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Quest Diagnostics (DGX) offers a strong dividend profile with a 1.71% yield, steady growth, and a sustainable payout, backed by solid profitability and financial health.
